Transaction Expands Edwards' Portfolio of Minimally Invasive Surgical
IRVINE, Calif., Dec. 21 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation (NYSE: EW), the world leader in the science of heart valves, announced today that it has completed its acquisition of certain assets of the CardioVations Division of Ethicon, Inc. CardioVations' product line includes the PORT-ACCESS products for performing minimally invasive cardiac valve procedures. The CardioVations product line is expected to generate sales of more than $20 million in 2008. It is not expected to have an impact on earnings in 2008 and will be accretive thereafter.
"We are pleased to add CardioVations' unique products to Edwards' portfolio of innovative aortic and mitral valve replacement technologies," said Anita B. Bessler, Edwards' corporate vice president, heart valve and cardiac surgery systems. "This complementary product line will give our surgical partners new avenues to optimize patient outcomes."
About Edwards Lifesciences
Edwards Lifesciences, a leader in advanced cardiovascular disease treatments, is the number-one heart valve company in the world and the global leader in acute hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards focuses on specific cardiovascular disease states including heart valve disease, peripheral vascular disease and critical care technologies. The company's global brands, which are sold in approximately 100 countries, include Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at http://www.edwards.com.
This news releas
|SOURCE Edwards Lifesciences Corporation|
Copyright©2007 PR Newswire.
All rights reserved